For research use only. Not for therapeutic Use.
Capecitabine（Cat No.:A000833）is an oral chemotherapy drug used to treat various cancers, including breast, colorectal, and gastric cancers. It is a prodrug, meaning it is inactive until metabolized into its active form, 5-fluorouracil (5-FU), in the body, particularly in tumor tissues. Capecitabine works by inhibiting DNA synthesis through the incorporation of 5-FU, which disrupts the replication of cancer cells. Its targeted conversion to 5-FU in cancer tissues helps minimize side effects compared to direct 5-FU administration. Common side effects include gastrointestinal symptoms, hand-foot syndrome, and myelosuppression.
| Catalog Number | A000833 |
| CAS Number | 154361-50-9 |
| Synonyms | 154361-50-9; Xeloda; Capiibine; Capecitibine; Caxeta |
| Molecular Formula | C15H22FN3O6 |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | >18mg/mL in DMSO |
| Storage | -20°C |
| IUPAC Name | pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate |
| InChI | InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 |
| InChIKey | GAGWJHPBXLXJQN-UORFTKCHSA-N |
| SMILES | CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O |
| Reference | 1: Hefner J, Berberich S, Lanvers E, Sanning M, Steimer AK, Kunzmann V. New <br> 3: Upadhyay M, Adena SKR, Vardhan H, Pandey S, Mishra B. Development and 4: Hattori M, Ishiguro H, Masuda N, Yoshimura A, Ohtani S, Yasojima H, Morita S, 5: Araujo-Mino EP, Patt YZ, Murray-Krezan C, Hanson JA, Bansal P, Liem BJ, Rajput 6: Sürmelioğlu N, Paydaş S, Karataş Y, Seydaoğlu G. Evaluation of lipid profiles <br> 8: Cornejo-Uixeda S, Escoin-Pérez C, Hernandez-Lorente E. Capecitabine induced <br> <br> |
